Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
NeoImmuneTech
National Cancer Institute (NCI)
AstraZeneca
Seagen Inc.
Pfizer
CytoDyn, Inc.
Incyte Corporation
Mayo Clinic
Formation Biologics
Numab Therapeutics AG
Washington University School of Medicine
Providence Health & Services
BeiGene
Sellas Life Sciences Group
University of Arkansas
ImmunityBio, Inc.
City of Hope Medical Center
The Methodist Hospital Research Institute
Fred Hutchinson Cancer Center
Genmab
Genmab
Nektar Therapeutics
Nektar Therapeutics
Corcept Therapeutics
Tesaro, Inc.
Incyte Corporation
Vanderbilt-Ingram Cancer Center
Novartis
Eisai Inc.
Calithera Biosciences, Inc
Incyte Corporation
Gilead Sciences
Novartis
Vanderbilt-Ingram Cancer Center
Ohio State University Comprehensive Cancer Center
Alliance for Clinical Trials in Oncology
Vanderbilt-Ingram Cancer Center